Cancer & Immunotheraphy

 

 

With so much activity around cancer vaccines and immunotherapy right now, can you afford to miss out? It is the place where the global market will come together to share the latest in early-stage scientific advancements, present clinical trial data, discuss new formulations of cancer vaccines and assess the future of combination treatments. Make sure that people are aware of the work you are doing to put yourself at the forefront of the industry.

 

DOWNLOAD DRAFT AGENDA

 

2018 AGENDA

 

Cancer & Immunotherapy, Wednesday 4 April 2018

Dr Niranjan Sardesai
Cancer & Immunotherapy
09:00

Chair’s opening remarks

Beyond Checkpoint Inhibitors

Dr Jay A. Berzofsky
Cancer & Immunotherapy
09:10

What’s next after PD1? Next generation checkpoint inhibitors including anti-TGF-beta

  • A deeper look at TGF-beta as a checkpoint inhibitor.
  • What are its effects on tumour growth and other cell types?
  • Synergy with vaccines and PD1 checkpoint inhibitors.
  • Brief look at other novel checkpoints, regulatory cells and cytokines; LAG3, Tim3
Panel discussion
Cancer & Immunotherapy
09:40

Panel Discussion: challenges to enhancing the therapeutic effectiveness of immune checkpoint antagonists with checkpoint agonists and inhibitors of immuno-metabolic pathways

  • Activating the antitumor immune T cell response through agonistic targets such as CD137 and OX40
  • Understanding the pathways used to create immune suppression and techniques to slow down immune suppression
  • What makes t-cell agonists so hard to work with vs checkpoint inhibitors?
Dr Ching Ching Leow, AVP, Immuno-Oncology Clinical Development, Eli Lilly and Company
10:40

Networking coffee break

Combination Therapy

Dr Roy Baynes
Cancer & Immunotherapy
11:40

PD-1 antibodies are transforming cancer therapy both as monotherapies and in combination

  • PD-1 antibody monotherapy indications continue to expand
  • PD-1 antibody has shown potential important activity when combined with:
    • Standard therapies e.g. chemotherapy
    • Targeted therapies e.g. with TKIs
    • Other immune modifying therapies e.g. IDO-1 inhibitors
    • Oncolytic viruses e.g. TVEC
  • Precision medicine will be increasingly important in patient selection
Dr Aiman Shalabi
Cancer & Immunotherapy
12:10

A comprehensive analysis of combination studies in immuno-oncology

  • Summary of all IO agents, targets and companies
  • Overview of ongoing PD-1 combination studies
  • Trends and areas to enhance efficiencies
  • Role of Philanthropy in IO
Dr Erin Karski
Cancer & Immunotherapy
12:40

Rapid and efficient development of combination therapies through a novel cancer immunotherapy platform.

  • Introduction to Morpheus; a novel cancer immunotherapy platform
  • How to go about selecting a combination study
  • Potential for use across several indications
1:10

Networking Lunch & Poster Session

Cancer Vaccines

Dr Michael Kalos
Cancer & Immunotherapy
2:40

State of the art and novel approaches to T Cell Vaccines

  • How have recent advances in immunotherapy provided a path forward for T-Cell Vaccines?
  • Biomarkers for T-cell strategies
Dr Douglas Mcneel
Cancer & Immunotherapy
3:10

Synergy of DNA Vaccines with checkpoint inhibitors

  • Selection of appropriate vaccine antigens for prostate cancer
  • Updates from ongoing translational trials of DNA vaccines in prostate cancer
Dr Allan B Dietz
Cancer & Immunotherapy
3:40

Hollow microneedles for use in delivery of cancer vaccines

  • Delivery to appropriate target tissue is critical to control the safety and effectiveness of vaccines 
  • We have used a new product developed by 3M to consistently for intradermal delivery of a cellular vaccine 
  • The unit is easy to load and deliver the product 
  • Our autologous DC vaccine using this product has shown evidence of efficacy for newly diagnosed glioblastoma patients.
Dr John Nieland
Cancer & Immunotherapy
3:55

The AAVLP platform for prophylactic and therapeutic vaccines with special focus on HPV-L2

  • Adeno Associated Virus Like Particles as a vaccine platform.
  • Broad coverage HPV vaccine without adjuvant, targeting the L2 minor capsid protein.
  • Prophylactic and therapeutic AAVLP-HER2/Neu vaccine.
4:10

Networking coffee break

Dr Michael Ciesielski
Cancer & Immunotherapy
4:40

Targeting cancer through SurVaxM, a new peptide immunotherapeutic vaccine

  • SurVaxM is a synthetic long peptide (SLP) vaccine with incorporated peptide mimic technology
  • Engineered to trigger a stronger immune response than wild type peptide, through better MHC binding 
  • Completed Phase 1 clinical trial in recurrent glioblastoma
  • Interim phase 2 data and designing a phase 3 trial
  • Exploring other indications and combination therapies
Panel discussion
Cancer & Immunotherapy
5:10

Panel Discussion: Tumor neoantigEn SeLection Alliance (TESLA) – discovering the keys to developing personalized cancer vaccines

  • Accurately identifying neo-epitopes
    • What is the diversity of neo-epitope predictions from different groups?
    • How well did these predictions perform in terms of patient sample analysis?
    • Can we identify key parameters that improve the ability to predict neo-epitopes?
  • How do we convert this data into the creation of personalized cancer vaccines?
    • Merits of different vaccines platforms
6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 16/Feb/18 15:30

Cancer & Immunotherapy, Thursday 5 April 2018

Dr Niranjan Sardesai
Cancer & Immunotherapy
09:00

Chair’s opening remarks

Cancer Vaccines Continued

Dr Ildiko Csiki
Cancer & Immunotherapy
09:10

DNA vaccines for cancer immunotherapy

  • Introduction to DNA plasmid and electroporation delivery technology
  • Updates in proof of concept studies from various trials
  • Head and neck cancer, bladder cancer, prostate cancer
  • Examples of potential combination partners
  • The regulatory landscape for DNA Vaccines
Dr Lakshmi Krishnan
Cancer & Immunotherapy
09:40

Archaeal lipid adjuvants and adenovirus vector delivery systems for cancer vaccine delivery Sulfated semi-synthetic archaeal lipids are potent modulators of vaccine immunity

  • A single lipid formulation can effectively deliver cancer antigens and provide protection in cancer models
  • Therapeutic benefit can be extended through combination vaccines with adenoviral vector antigen delivery and check-point inhibitor blockade
Cancer & Immunotherapy
09:55

Overcoming the limitations of viral vectors whilst still maintaining superior generation and expansion of CTLs

Oncoviruses

Dr Scot Roberts
Cancer & Immunotherapy
10:10

Densigen, a versatile immunotherapeutic platform to promote broad and robust T cell immunity against viral infections and cancer

  • Densigens are rationally designed, CD4+/CD8+ T cell epitope-containing peptides modified by a fluorocarbon moiety providing self-adjuvanting properties
  • Densigen-based immunotherapeutics promote robust T cell responses in humans while achieving broad population coverage
  • Densigens simultaneously target multiple antigenic determinants to prevent immune escape
  • Prime-boost immunizations with Densigens can act synergistically to promote better T cell responses
10:40

Networking coffee break

Dr Corey Casper
Cancer & Immunotherapy
11:30

Translational Studies Informing the Design and Feasibility of a vaccine against Epstein Barr Virus

  • Opportunities for the development of a vaccine against EBV
  • Understanding the medical necessity, market potential and public health use of EBV Vaccine.
  • The science behind the 3 vaccine candidates that currently exist:
    • Pre-clinical safety data
    • Updates on progress of phase 1 trials.
Dr Eliav Barr
Cancer & Immunotherapy
12:00

Advances in the development of a replication-deficient human cytomegalovirus vaccine for the prevention of congenital infection

  • The Burden of Disease caused by maternal/fetal/infant CMV infection
  • Natural History of maternal/fetal/infant CMV infection
  • Merck’s CMV vaccine candidate
  • Strategies to demonstrate the efficacy and safety profiles of CMV vaccines targeted to prevent congenital CMV infection
12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

Dr Angela Shen
1:40

Report on U.S. vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development

  • A combined effort from HHS, NIH, CDC, FDA, BARDA to promote innovation in the development of vaccines that minimize the burden of infectious disease
  • What is the optimal process to determine which vaccines would be beneficial to public health and how information on such vaccines is disseminated to key stakeholders
  • Identifying whether obstacles exist that inhibit the development of beneficial vaccines
  • Recommendations on how best to promote and incentivize vaccine innovation and development
Dr Jeffrey Stoddard
2:10

Zoster vaccine recombinant, adjuvanted: A journey from research to approval

  • Non-live, recombinant vaccine to help prevent herpes zoster (shingles), combining glycoprotein E with an adjuvant system, AS01
  • Sharing positive results from Phase III revaccination study 
Dr Walter A Orenstein
2:40

With polio eradication succeeding, should measles eradication come next?

  • Changing the perception from polio: Focusing on measles elimination to build our overall immunization program
  • Using a “diagonal” approach when dealing with highly contagious preventable diseases like measles
  • Surveillance -  a weakness in our system?
  • Cost of controlling outbreaks and the consequences
Dr Paul Offit
3:10

Vaccine hesitancy: How to respond to the media to advance better health

  • Challenges to communicating science through the opaque prism of the media
  • How certain cultural biases can influence the perception of science 
3:40

3:40 Chair closing remarks and end of congress

last published: 16/Feb/18 15:30

 

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071